MO11-1 Efficacy of durvalumab after chemoradiotherapy with daily low-dose carboplatin for unresectable locally advanced NSCLC

Abstract

On the basis of the PACIFIC trial, the standard of care for unresectable stage III non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by 1 year of durvalumab consolidation therapy. Although CRT with platinum doublet is standard, low-dose carboplatin (CBDCA) is widely used in Japan for patients who are not eligible for platinum-based doublet chemotherapy. However, because only five patients received low-dose CBDCA in the PACIFIC study, the efficacy of durvalumab after CRT with low-dose CBDCA remains unclear.